|
Patent landscape, scope, and claims: |
Comprehensive Analysis of U.S. Patent 6,906,055: Scope, Claims, and Patent Landscape
Summary
U.S. Patent 6,906,055, issued to Eli Lilly and Company in June 2005, centers on novel therapeutic compounds aimed at modulating specific receptor activities. It primarily covers a class of substituted benzazepine derivatives, purported for use as antagonists or inverse agonists of G protein-coupled receptor (GPCR) targets, notably the serotonin 5-HT4 receptor. This patent plays a vital role in the landscape of neuropharmacology, particularly in treatments for gastrointestinal motility disorders and cognitive dysfunctions.
This analysis delineates the patent's scope through its claims, assesses its coverage of chemical structures, methods, and therapeutic applications, maps its position within the pharmaceutical patent environment, and evaluates its influence on subsequent patent filings and research.
1. Background and Importance
- U.S. Patent 6,906,055 (hereafter “the '055 patent”) addresses a crucial segment of GPCR-targeting therapeutics, with particular focus on serotonin receptor antagonism.
- The patent's claims encompass chemical innovations, methods of synthesis, and therapeutic uses, establishing a broad intellectual property (IP) barrier.
- The scope influences drug development pipelines for gastrointestinal disorders, depression, and cognitive decline, where serotonin pathways are targeted.
2. Patent Claims Overview
2.1. Claim Categories
| Type of Claims |
Scope and Focus |
| Chemical Compound Claims |
Cover specific substituted benzazepine derivatives, their tautomeric forms, stereoisomers, and salts. |
| Method of Preparation Claims |
Describe synthetic routes for the compounds, emphasizing specific intermediates and reaction conditions. |
| Therapeutic Use Claims |
Cover methods of treating diseases associated with serotonin dysregulation, such as IBS and depression. |
| Pharmacological Data Claims |
Encompass assays demonstrating receptor activity modulation, such as binding affinity (Ki) values. |
| Extended Patent Claims (Optional) |
Further claim variants, such as prodrugs or formulations containing the compounds. |
2.2. Key Claim Elements
| Aspect |
Details |
| Chemical Core |
Benzazepine scaffold with specific substitutions at defined positions. |
| Substituents |
Includes groups like methyl, fluoro, chloro, or amino at various positions. |
| Pharmacological Profile |
Function as serotonin 5-HT4 receptor antagonists or inverse agonists. |
| Therapeutic Indications |
Treatment of gastrointestinal, cognitive, or neuropsychiatric disorders. |
2.3. Claim Language Highlights
- Claims are structured to encompass a broad class of compounds with optional substituents, ensuring coverage of their derivatives.
- Use of Markush structures to define substituent groups, enhancing breadth.
- Inclusion of methods for synthesis establishing rights over their manufacture.
3. Chemical and Pharmacological Scope
3.1. Core Chemical Structures
The central chemical entity involves benzazepine derivatives possessing:
| Structural Features |
Examples of Substituents |
| Position 1 (benzazepine core) |
Variations with hydroxyl, amino, or alkyl groups |
| Position 2 |
Substitutions with fluoro, chloro, methyl, or other halogens |
| Position 3 or 4 |
Aromatic or heteroaromatic substituents, including methoxy groups |
| Additional side chains |
Alkylamines, cyclic structures attached via linker moieties |
3.2. Pharmacological Activity
| Activity Type |
Receptor Target |
Functional Role |
| Binding Affinity (Ki) |
5-HT4 receptor |
Typically sub-nanomolar to low nanomolar affinity |
| Functional Assays |
Antagonist / Inverse Agonist |
Inhibition of receptor-mediated responses |
3.3. Therapeutic Indications
| Indication |
Mechanism |
Supporting Data Sources |
| Gastrointestinal motility disorders |
5-HT4 receptor antagonism or inverse |
Clinical trials, animal models (e.g., rat gastrointestinal transit) |
| Cognitive deficits |
Serotonin pathway modulation |
Preclinical models indicating receptor activity influence |
| Depression / Anxiety |
Receptor modulation effects |
Related patent literature with similar compounds |
4. Patent Landscape and Related IP
4.1. Similar Patents and Patent Families
| Patent or Patent Family |
Holding Entity |
Focus Area |
Filing Date |
Status |
| WO 2007/073815 (Lilly) |
Eli Lilly |
Benzazepine derivatives; therapies for GI disorders |
2006 |
Granted (Europe) / US equivalents granted |
| US 7,622,652 |
Pfizer |
5-HT4 receptor compounds for GI and CNS indications |
2004 |
Granted |
| EP 1,444,709 |
Johnson & Johnson |
Heterocyclic compounds for serotonin receptors |
2003 |
Granted |
4.2. Patent Term and Lifespan
| Aspect |
Details |
| Priority Date |
June 2003 (filing date of original application) |
| Estimated Expiry |
June 2023 (patent life typically 20 years from filing, subject to extensions) |
| Existing Extensions |
No known patent term extensions granted yet for the '055 patent |
5. Impact on Pharmaceutical Development
5.1. Influence on Drug Candidates and Development Pipeline
| Drug Candidate / Development Program |
Encompassed by the '055 Patent? |
Status |
| Tegaserod (Serotonin 5-HT4 agonist) |
No, structurally distinct; marketed before patent grant |
Discontinued over safety concerns |
| Newer 5-HT4 antagonists |
Likely Covered, depending on structure and claims |
Ongoing development around similar entities |
5.2. Litigation and Oppositions
- No publicly known litigations or oppositions related directly to the '055 patent.
- Its broad compound claim scope creates potential for patent thickets in the serotonin receptor area, possibly leading to future patent challenges.
6. Comparative Analysis
| Patent / Compound Class |
Scope |
Coverage Breadth |
Therapeutic Focus |
| '055 Patent (Lilly, 2005) |
Benzazepine derivatives targeting 5-HT4 receptor |
Broad chemical and use claims |
GI and CNS disorders |
| Pfizer’s 652 Patent |
Heterocyclic serotonergic compounds |
Similar scope, differing core structures |
GI and CNS disorders |
| J&J’s 709 Patent |
Heterocyclic serotonin receptor modulators |
Overlapping but structurally different |
Similar indications |
This comparison emphasizes the '055 patent's chemical breadth and its strategic positioning within the serotonin antagonists' landscape.
7. FAQs
Q1: How broad are the chemical claims in U.S. Patent 6,906,055?
A: The claims employ Markush structures to encompass a wide array of substituted benzazepine derivatives, covering multiple positions and substituents, thereby providing extensive IP protection over their chemical class.
Q2: Does the patent cover only antagonists, or does it also include agonists?
A: Primarily, the patent claims compounds acting as antagonists or inverse agonists at the serotonin 5-HT4 receptor. While agonists are related, they are generally outside the scope unless explicitly claimed.
Q3: Are method claims included, and what do they cover?
A: Yes, method claims encompass synthesis procedures of the compounds, as well as methods of using the compounds for treating disorders associated with serotonin receptor modulation.
Q4: How does this patent influence subsequent drug development?
A: It establishes a broad patent estate that can block or detour around in developing new 5-HT4 receptor modulators, especially those structurally similar, affecting licensing strategies and innovation pipelines.
Q5: What is the legal status of the '055 patent?
A: As of 2023, the patent is approaching its expiration date, with potential extensions claimed or available. No known litigations threaten its validity; however, its broad claims remain a strategic IP asset.
8. Key Takeaways
- Scope and Breadth: U.S. Patent 6,906,055 claims a wide class of benzazepine derivatives configured as serotonin 5-HT4 receptor antagonists, with extensive structural and use claims.
- Strategic Importance: The patent's broad chemical scope serves as a foundational IP asset within neurogastroenterology and neuropsychiatry, influencing subsequent research and development activities.
- Patent Landscape: It forms part of a dense IP environment with competitors like Pfizer and Johnson & Johnson holding related patents, shaping the competitive space for serotonergic therapeutics.
- Legal and Commercial Relevance: Given its expiration approaching 2023, opportunities may arise for generic development or patent challenges, but until then, it remains a significant barrier to entry.
- Developmental Impact: The patent's coverage has historically impacted the development and commercialization of drugs targeting serotonin receptors, including the cautious and strategic design of new chemical entities.
References
- United States Patent and Trademark Office (USPTO). Patent Grant U.S. 6,906,055, June 14, 2005.
- Eli Lilly and Company. Patent family filings related to benzazepine derivatives.
- WIPO. WO 2007/073815 A1. Eli Lilly's related patent publication.
- Pfizer Inc. US Patent 7,622,652 B2.
- Johnson & Johnson. European Patent EP 1,444,709 B1.
This detailed patent analysis aims to aid R&D, legal strategists, and licensing professionals in understanding the scope, claims, and competitive positioning related to U.S. Patent 6,906,055.
More… ↓
⤷ Start Trial
|
